Verapamil reduces the size of reperfused ischemically injured myocardium in hypertrophied rat hearts as assessed by magnetic resonance imaging

American Heart Journal

Volumn 131, Issue 1, 1996, Pages 14-23

  Lauerma, Kirsi ^a   Saeed, Maythem ^a   Wendland, Michael F ^a   Derugin, Nikita ^a   Yu, Kyle K ^a   Higgins, Charles B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOTERIDOL; TRIPHENYLTETRAZOLIUM; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT;

EID: 0030050911     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90045-9     Document Type: Article

References (44)

1. Messerli FH, Ventura HO, Elizandi DJ, Dunn FG, Frolich ED. Hypertension and sudden death: increased ventricular activity in left ventricular hypertrophy. Am J Med 1984;77:18-22.
2. Kannel WB. Hypertension and the risk of cardiovascular disease, In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press, Ltd, 1990:101-16.
3. Koyhanagi S, Eastham CL, Harrison DG, Marcus ML. Increased size of myocardial infarction in dogs with chronic hypertension and left ventricular hypertrophy. Circ Res 1982;50:55-60.
4. Buser PT, Wikman-Coffelt J, Wu ST, Derugin N, Parmley WW, Higgins CB. Postischemic recovery of mechanical performance and energy metabolism in the presence of left ventricular hypertrophy. A 31P-MRS study. Circ Res 1990;66:735-46.
5. Lauerma K, Saeed M, Wendland MF, Derugin N, Yu KK, Higgins CB. Gadoteridol-enhanced MR imaging in the assessment of the tolerance of hypertrophied myocardium to ischemia. Invest Radiol 1994;29:527-35.
6. Holtz J, Restorff WV, Bard P, Bassenge E. Transmural distribution of myocardial blood flow and of coronary reserve in canine left ventricular hypertrophy. Basic Res Cardiol 1977;72:286-92.
7. Batra S, Rakusan K, Campbell SE. Geometry of capillary networks in hypertrophied rat heart. Microvasc Res 1991;41:29-40.
8. Kleinman RB, Houser SR. Calcium currents in normal and hypertrophied isolated feline ventricular myocytes. Am J Physiol 1988; 255:H1434-42.
9. Keung EC. Calcium current is increased in isolated adult myocytes from hypertrophied rat myocardium. Circ Res 1989;64:753-63.
10. Daluz PL, Monteiro deParras LF, Leite JJ, Pileggi F, Decourt LV. Effects of verapamil on regional coronary myocardial perfusion during acute coronary occlusion. Am J Cardiol 1980;45:264-75.
11. DeBoer LWV, Strauss HW, Kloner RA, Rude RE, Davis RF, Maroko PR, Braunwald E. Autoradiographic method for measuring the ischemic myocardium at risk: effects of verapamil on infarct size after experimental coronary artery occlusion. Proc Natl Acad Sci U S A 1980;77:6119-23.
12. Roberts R. Thrombolysis and its sequelae: calcium antagonists as potential adjunctive therapy. Circulation 1989;80:IV-93:IV-102.
13. Saeed M, Holtz J, Elsner D, Bassenge E. Attenuation of sympathetic vasoconstriction by nifedipine: the role of vascular alpha-2 adrenoceptors. Eur J Pharmacol 1983;94:149-53.
14. Saeed M, Hartmann A, Bing RJ. Nisoldipine as a vasodilator in endothelium-deprived large coronary arteries of isolated working rabbit hearts. Eur Heart J 1989;10:159-63.
15. Holt WW, Wendland MF, Derugin N, Wolfe C, Saeed M, Higgins CB. Effect of nicardipine, a calcium channel antagonist, on myocardial salvage and high energy phosphate stores in reperfused myocardial injury. J Am Coll Cardiol 1990;16:1736-44.
16. Buser PT, Wagner S, Wu ST, Derugin N, Parmely WW, Higgins CB, Wikman-Coffelt J. Verapamil preserves myocardial performance and energy metabolism in left ventricular hypertrophy following ischemia and reperfusion. Circulation 1989;80:1837-45.
17. Lo H-M, Kloner RA, Braunwald E. Effect of intracoronary verapamil on infarct size in the ischemic, reperfused canine heart: critical importance of the timing of treatment. Am J Cardiol 1985;56:672-7.
18. Higgins CB, Saeed M, Wendland MF, Yu KK, Lauerma K, Dulce M, Kanth N. Contrast media for cardiothoracic MR imaging. JMRI 1993; 3:265-76.
19. Saeed M, Wendland MF, Takehara Y, Masui T, Higgins CB. Reperfusion and irreversible myocardial injury: identification with a nonionic MR imaging contrast medium. Radiology 1992;182:675-83.
20. van Rossum AC, Visser FC, van Eenige MJ, Sprenger M, Valk J, Verheugt FWA, Roos JP. Value of gadolinium-diethylene-triamine pentaacetic acid dynamics in magnetic resonance imaging of acute myocardial infarction with occluded and reperfused coronary arteries after thrombolysis. Am J Cardiol 1990;65:845-51.
21. Tweedle MF. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992;27:S2-6.
22. Soltys RA. Summary of preclinical safety evaluation of gadoteridol injection. Invest Radiol 1992;27:S7-S11.
23. Harapat SR, Kates RE. High-performance liquid chromatographic analysis of verapamil. II Simultaneous quantitation of verapamil and its active metabolite, norverapamil. J Chromatography 1980;181:484-9.
24. de Roos A, Mathiejssen NAA, Doornbos J, van Dijkman PR, van Voorthusien AE, van der Wall EE. Myocardial infarction size after reperfusion therapy: assessment with Gd-DTPA-enhanced MR imaging. Radiology 1990;176:517-21.
25. Saeed M, Wendland MF, Masui T, Higgins CB. Reperfused myocardial infarctions on T1- and susceptibility enhanced MRI: evidence for loss of compartmetalization of contrast media. Magn Reson Med 1994; 31:31-9.
26. Krauss XH, van der Wall EE, Doornbos J, Blokland JAK, Postema S, de Roos A, van der Laarse A, Cats VM, van Voorthusien AE, Bruschke AVG. Value of magnetic resonance imaging in patients with a recent myocardial infarction: comparison with planar thallium-201 scintigraphy. Cardiovasc Intervent Radiol 1989;12:119-24.
27. French WJ, Garner D, Adomian GE, Averill W, Laks MM. Verapamil induced ventricular hypertrophy in conscious dogs. Cardiovasc Res 1989;23:695-701.
28. Agabiti-Rosei E, Muiesan ML, Romanelli G, Castellano M, Beschi M, Corea L, Muiesan G. Similarities and differences in the antihypertensive effect of two calcium antagonist drugs, verapamil and nifedipine. J Am Coll Cardiol 1986;7:916-24.
29. Nishimura T, Yamada Y, Haze K, Nagata S. Experience using Gadolinium DTPA in cardiovascular MRI. Magn Reson Med 1991;22:354-7.
30. Schmiedar RE, Mersserli FH, Garavaglia GE, Nunez BD. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 1987;75:1030-6.
31. Smith HJ, Goldstein RA, Griffith JM, Kent KM, Epstein SE. Regional contractility. Selective depression of ischemic myocardium by verapamil. Circulation 1976;54:629-35.
32. Nayler WG, Ferrari R, Williams A. Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium. Am J Cardiol 1980; 46:242-8.
33. Laks MM, Morady F. Norepinephrine: the myocardial hypertrophy hormone? AM HEART J 197;91:674-5.
34. Sullivan AT, Baker DJ, Drew GM. Effect of calcium channel blocking agents on infarct size after ischemia-reperfusion in anesthetized pigs: relationship between cardioprotection and cardiodepression. J Cardiovasc Pharmacol 1991;17:707-17.
35. Geschwind JF, Wendland MF, Saeed M, Lauerma K, Derugin N, Higgins CB. Identification of myocardial cell death in reperfused myocardial injury using a dual mechanism of contrast enhanced magnetic resonance imaging. Acad Radiol 1994;1:1-8.
36. Pereira RS, Prato FS, Tong CY, Sykes J, Wisenberg G. The relationship between myocardial viability and the distribution volume of Gd-DTPA in a canine model of reperfusion and infarction injury. In: Proceedings of the Society of Magnetic Resonance in Medicine 1994. San Francisco, 1492.
37. Kloner RA, Fishbein MC, Hare CM, Maroko PR. Early ischemic ultra-structural and histochemical alterations in the myocardium of the rat following coronary artery occlusion. Exp Mol Pathol 1979;30:129-43.
38. Bing RJ, Castellanos A, Gadel E, Lupton C, Siegel A. Experimental myocardial infarction: circulatory, biochemical, and pathologic changes. Am J Med Sci 1956;232:533-54.
39. Lie JT, Pairolero PC, Holley KE, Titus JL. Macroscopic enzyme-mapping verification of large, homogeneous, experimental myocardial infarcts of predictable size and location in dogs. Cardiovasc Surg 1975;69: 599-605.
40. Liu Y, Downey JM. Preconditioning against infarction in the rat heart does not involve a pertussis toxin sensitive G protein. Cardiovasc Res 1993;27:608-11.
41. Liu J, Tanonaka K, Sanbe A, Yamamoto K, Takeo S. Beneficial effects of quinidine on post-ischemic contractile failure of isolated rat hearts. J Mol Cell Cardiol 1993;25:1249-63.
42. Freeman I, Grunwald AM, Robin B, Rao PS, Bodenheimer M. Effect of early reperfusion on use of triphenyltetrazolium chloride to dirrentiate viable from non-viable myocardium in area of risk. Cardiovasc Res 1990;24:109-14.
43. Hochman JS, Bulkley BH. Expansion of acute myocardial infarction: an experimental study. Circulation 1982;65:1446-50.
44. Rogers WJ, Hood WP Jr, Mantle JA, Baxley WA, Kirklin JK, Zorn GC, Nath HP. Return of left ventricular function after reperfusion in patients with myocardial infarction: importance of subtotal stenoses or intact collaterals. Circulation 1984;69:338-49.